Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Molecular Partners AG ADR (MOLN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: MOLN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $10.71
1 Year Target Price $10.71
| 3 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 28.94% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 136.11M USD | Price to earnings Ratio - | 1Y Target Price 10.71 |
Price to earnings Ratio - | 1Y Target Price 10.71 | ||
Volume (30-day avg) 4 | Beta 0.48 | 52 Weeks Range 3.36 - 7.60 | Updated Date 09/17/2025 |
52 Weeks Range 3.36 - 7.60 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.25 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-25 | When - | Estimate -0.4995 | Actual -0.6841 |
Profitability
Profit Margin - | Operating Margin (TTM) -8843.47% |
Management Effectiveness
Return on Assets (TTM) -25.53% | Return on Equity (TTM) -49.42% |
Valuation
Trailing PE - | Forward PE 1.78 | Enterprise Value -8827206 | Price to Sales(TTM) 199.87 |
Enterprise Value -8827206 | Price to Sales(TTM) 199.87 | ||
Enterprise Value to Revenue 3.81 | Enterprise Value to EBITDA 1.23 | Shares Outstanding 37392400 | Shares Floating 15404155 |
Shares Outstanding 37392400 | Shares Floating 15404155 | ||
Percent Insiders - | Percent Institutions 9.73 |
Upturn AI SWOT
Molecular Partners AG ADR
Company Overview
History and Background
Molecular Partners AG was founded in 2004 in Zurich, Switzerland. It focuses on developing a new class of custom-built protein therapeutics known as DARPinu00ae therapeutics.
Core Business Areas
- DARPin Therapeutics: Developing and commercializing DARPin therapeutics for various diseases, including oncology and ophthalmology.
- Clinical Development: Conducting clinical trials to evaluate the safety and efficacy of DARPin candidates.
- Research and Development: Discovering and developing new DARPin molecules and expanding the DARPin platform.
- Partnering and Licensing: Collaborating with pharmaceutical companies for the development and commercialization of DARPin therapeutics.
Leadership and Structure
The leadership team consists of senior executives with expertise in drug development, finance, and business strategy. The organizational structure is centered around research, clinical development, and commercial operations.
Top Products and Market Share
Key Offerings
- Ensovibep (MP0420): A DARPin therapeutic developed in collaboration with Novartis for the treatment of COVID-19. While initial promise was shown, it faces competition from other COVID-19 treatments such as Pfizer's Paxlovid and Merck's Molnupiravir. Market share is dependent on regulatory approvals and commercialization strategies in different regions.
- MP0310: MP0310 is a FAP-IL2v, a DARPin therapeutic candidate for cancer immunotherapy, currently in clinical trials. The primary competition comes from other cancer immunotherapies such as checkpoint inhibitors and CAR-T cell therapies. Market share is not yet defined.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by intense competition, high research and development costs, and stringent regulatory requirements. There's a growing focus on personalized medicine and innovative therapies.
Positioning
Molecular Partners AG is positioned as an innovative biopharmaceutical company focused on developing DARPin therapeutics. Its competitive advantage lies in the unique properties of DARPins, which offer potential advantages over antibodies in terms of target binding and manufacturing.
Total Addressable Market (TAM)
The TAM for Molecular Partners depends on the indications pursued by their DARPin therapeutics. For oncology and COVID-19, the TAM is in the billions of dollars. Molecular Partners' position depends on successful clinical trials and commercialization efforts.
Upturn SWOT Analysis
Strengths
- DARPin technology platform
- Strong intellectual property portfolio
- Strategic partnerships with established pharmaceutical companies
- Innovative approach to drug development
Weaknesses
- Limited commercialization experience
- Reliance on partnerships for product development and commercialization
- High research and development costs
- Negative cash flow and funding concerns
Opportunities
- Expanding DARPin applications to new therapeutic areas
- Securing additional partnerships to accelerate product development
- Positive clinical trial results for key DARPin candidates
- Regulatory approval and market launch of DARPin therapeutics
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
- Intellectual property challenges
- Economic downturns impacting R&D funding
Competitors and Market Share
Key Competitors
- LLY
- AMGN
- MRK
- PFE
- NVS
Competitive Landscape
Molecular Partners AG faces significant competition from established pharmaceutical companies with greater resources and commercialization capabilities. Its competitive advantage lies in its DARPin technology platform, which offers potential advantages over traditional antibodies. However, the company needs to demonstrate the clinical and commercial viability of its DARPin therapeutics to gain a significant market share.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by research and development progress, partnerships, and clinical trial advancements.
Future Projections: Future growth is dependent on the success of clinical trials, regulatory approvals, and commercialization efforts. Analyst estimates are not widely available.
Recent Initiatives: Recent initiatives include focusing on key DARPin candidates and expanding partnerships.
Summary
Molecular Partners AG is a biopharmaceutical company with an innovative DARPin technology platform. Its success hinges on positive clinical trial results and successful commercialization or partnering of its DARPin candidates. The company's limited commercial experience and high research and development costs present challenges. However, strategic partnerships and expanding DARPin applications could drive future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Financial News Outlets
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It is not financial advice, and investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Molecular Partners AG ADR
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-06-16 | Co-Founder, CEO, Member of Management Board & Director Dr. Patrick Amstutz Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 153 | |
Full time employees 153 | |||
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in preclinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and Radio-DARPin Therapy to treat ovarian disease. In addition, the company develops MP0621, a molecular partners' first Switch-DARPin program, which is in preclinical trial designed to induce killing of hematopoietic stem cells (HSCs) as a next-generation conditioning regimen for HSC transplantation (HSCT); and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.